
Multimodal Injection for Postoperative Pain Control in Pediatric Patients With Cerebral Palsy

Multimodal Injection for Postoperative Pain Control in Pediatric Patients With Cerebral Palsy
Efficacy of a Multimodal Surgical Site Injection for Postoperative Pain Control in Pediatric Patients With Cerebral Palsy Undergoing Hip Reconstruction: A Randomized Controlled Trial.
J Pediatr Orthop . 2024 Nov-Dec;44(10):e921-e928.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Thirty-four pediatric patients with cerebral palsy undergoing hip reconstruction were randomized to receive either a multimodal surgical site injection containing ropivacaine (3 mg/kg), epinephrine (0.5 mg), and ketorolac (0.5 mg/kg) (n=17) or a placebo injection of normal saline (n=17). The primary outcome of interest was total narcotic consumption, measured in morphine equivalents per kilogram (...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.